Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: EtTuBrute who wrote (76649)	2/17/2000 2:39:00 PM
From: marquis103	Read Replies (2) \| Respond to of 108040

AIMM. With biotechs so hot, everyone's waiting for AIMM to have its turn. Russ AutoImmune Inc. is a biopharmaceutical company developing a new class of orally administered pharmaceutical products for the treatment of autoimmune and other cell-mediated inflammatory diseases and conditions. The Company is currently conducting clinical trials for products that include: Colloral(R), for the treatment of rheumatoid arthritis; AI 502, for the treatment of chronic transplant rejection; AI 401, for the treatment of Type 1 diabetes; AI 502, for the prevention of organ transplant rejection; AI 301, for the treatment of uveitis; and products for Multiple Sclerosis and Myasthenia Gravis. AutoImmune's proprietary approach to therapy can induce tissue-specific immunosuppression without toxicity or significant side effects. Additional clinical and commercial advantages of this approach include the ability to administer products orally and the potential for application to a variety of inflammatory diseases and conditions.